AUG 1 6 2012

5. 510(K) Summary

510(K) SUMMARY: AGFA DX-D Imaging Package

Regulation Name: Image Intensified fluoroscopic x-ray system (21 CFR 892.1650)

Classification Name: Solid state x-ray imager (flat panel/digital imager) (product code MQB)

Common Name: Direct radiography system Proprietary Name: DX-D Imaging Package

Agfa HealthCare N.V.

Septestraat 27 B-2640 Mortsel

Belgium

Contact: Phil Cuscuna, Prepared: January 15, 2012

Telephone: (416) 240-7317 Facsimile: (416) 240-7359

A. LEGALLY MARKETED PREDICATE DEVICES

This is a 510(k) for the latest version of Agfa's DX-D Imaging Package, a solid state, flat-panel x-ray imaging system.

B. DEVICE DESCRIPTION

The device is a direct radiography imaging system of similar design and construction to the predicate. Agfa's DX-D Imaging Package uses the company's familiar NX workstation with MUSICA² TM image processing and flat panel detectors of the scintillator-photodetector type. Flat panel detectors with scintillators of both Cesium Iodide (CsI) and Gadolinium Oxysulfide (GOS) are available. The device is used to capture and directly digitize x-ray images without a separate digitizer common to computed radiography systems. This new version uses a previously cleared detector with wireless communication capability.

The device uses a direct conversion process to convert x-rays into a digital signal. X-rays incident on the scintillator layer of the detector generate light that is absorbed by photo-detectors, converted to a digital signal and sent to the workstation. At the workstation the data is processed by Agfa's MUSICA² image processing software. The acronym MUSICA stands for **Multi-Stage-Image-Contrast-Amplification**. MUSICA² acts on the acquired images to preferentially enhance the diagnostically relevant, moderate and subtle contrasts.

Principles of operation and technological characteristics of the new and predicate devices are the same.

C. INTENDED USE

Agfa's DX-D Imaging Package is indicated for use in general projection radiographic applications to capture for display diagnostic quality radiographic images of human anatomy. The

DX-D Imaging Package may be used wherever conventional screen-film systems may be used. Agfa's DX-D Imaging Package is not indicated for use in mammography.

D. SUBSTANTIAL EQUIVALENCE SUMMARY

Agfa's DX-D Imaging Package has an Indications For Use statement similar to the statements for the predicate device, K092669. Intended uses are the same. The devices have the same technological characteristics. Descriptive characteristics and performance data are adequate to ensure equivalence.

The device does not have therapeutic effects. Differences in new device and the predicate do not alter the intended diagnostic effect.

PRODUCT COMPARISON TABLE		
	DX-D Imaging Package (New Device)	AGFA DX-D Imaging Package (PREDICATE-K092669)
Communications	DICOM .	DICOM
Flat Panel Manufacturer	Varian Medical Systems (wired detectors) Canon (wireless detector)	Varian Medical Systems
Detector Material	Varian: Gadolinium Oxysulfide (GOS), or Varian & Canon: Cesium Iodide (CSI)	Gadolinium Oxysulfide (GOS) or Cesium Iodide (CSI) scintillator
Detector Sizes	17x17 in. 14x17 in.	17x17 in. 14x17 in.
Active Matrix (14x17 in.)	2560x3072 (Varian) 2800x3408 (Canon)	2560x3072
Pixel size	139 μm (Varian), or 125 μm (Canon)	139 μm
Dynamic Range	14 bit	14 bit
Maximum Image Acquisitions/hr.	150	150
Power Supply	47-63 Hz 90-264V auto ranging	47-63 Hz 90-264V auto ranging
Operator Workstation	Agfa NX	Agfa NX
Image processing	MUSICA ²	MUSICA ²
Operating system	Windows 7	Windows XP Pro
Display System	Standard PC display or separately cleared medical display (e.g. K051901)	Standard PC display or separately cleared medical display (e.g. K051901)

E. TECHNOLOGICAL CHARACTERISTICS

Agfa's DX-D Imaging Package is a scintillator-photodetector type solid state x-ray imaging system. The device provides the user with a choice of three wired or wireless flat panel detectors to capture and digitized the image. A computer workstation allows users view and process images, and forward them to other devices (e.g. a PACS or printer).

The DX-D Imaging Package is integrated with compatible x-ray systems.

F. TESTING

Image quality measurements have been completed. Image quality comparisons between the new and predicate devices have been performed as well. Sample images have been provided.

Performance of the complete system has been validated.

No clinical testing was performed in the development of the DX-D Imaging Package.

The product, manufacturing and development processes have been shown to conform to product safety, radiology, and imaging standards including:

PRODUCT STANDARDS

- IEC 60601-1: Medical electrical equipment Part 1: General requirements for basic safety and essential performance, plus collateral standard: Electromagnetic compatibility - requirements and tests.
- IEC 60601-1-2: Medical electrical equipment Part 1-2: General Requirements For Safety Collateral Standard: Electromagnetic Compatibility Requirements And Tests
- ACR/NEMA PS3.1-3.18: Digital Imaging and Communications in Medicine (DICOM)


MANAGEMENT STANDARDS

- ISO 14971 Application of Risk Management to Medical Devices
- ISO 13485 Medical Devices Quality Management Systems Requirements For Regulatory purposes

G. CONCLUSIONS

This 510(k) has demonstrated Substantial Equivalence as defined and understood in the Federal Food Drug and Cosmetic Act and various guidance documents issued by the Center for Devices and Radiological Health.





Food and Drug Administration 10903 New Hampshire Avenue Document Control Room – WO66-G609 Silver Spring, MD 20993-0002

Agfa Healthcare N.V. % Mr. Mark Job Responsible Third Party Official Regulatory Technology Services LLC 1394 25th Street NW BUFFALO MN 55313

AUG 1 6 2012

Re: K121095

Trade/Device Name: DX-D Imaging Package

Regulation Number: 21 CFR 892.1650

Regulation Name: Image-intensified fluoroscopic x-ray system

Regulatory Class: II Product Code: MQB Dated: April 24, 2012 Received: April 25, 2012

Dear Mr. Job:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely Yours,

Janine M. Morris Acting Director

Division of Radiological Devices Office of In Vitro Diagnostic Device

Evaluation and Safety

Center for Devices and Radiological Health

Enclosure

Indications for Use Form

	·
510(k) Number (if known):	
Device Name: DX-D Imaging Package	
Indications for Use:	
Agfa's DX-D Imaging Package is indicated for use in generato capture for display diagnostic quality radiographic imaging Package may be used wherever conventional scre	ges of human anatomy. The DX-D
Agfa's DX-D Imaging Package is not indicated for use in m	ammography.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR	Over-The-Counter Use(21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINU Concurrence of CDRH, Office of In Vitro D	
Juhul D & Man	
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety	
510(k) K121095	Page 1 of